Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals (TPEX: 6576) is a Taiwan/US-based biopharmaceutical company pioneering SIF (Stabilized Injectable Formulation) long-acting injectable (LAI) technology. Its product CAMCEVI® (leuprolide mesylate 21 mg, quarterly LAI) received FDA approval for advanced prostate cancer. SIF pipeline includes candidates for breast cancer, opioid addiction, and neurological diseases.